Therapy News and Research

RSS

Risk of having a potentially fatal blood clot after surgery is higher, finds research

The risk of having a potentially fatal blood clot after surgery is higher and lasts for longer than had previously been thought, concludes new research published on bmj.com today.

4 Dec 2009

FDA approves St. Jude Medical's MultiSteering Technology software for optimizing neurostimulation therapy

St. Jude Medical, Inc. today announced U.S. Food and Drug Administration (FDA) approval of its next-generation MultiSteering Technology software for Rapid Programmer™, a programming platform used to optimize neurostimulation therapy for chronic pain patients.

4 Dec 2009

Santaris Pharma's LNA technology based microRNA-targeted therapy holds promise for HCV

A study published online in this week's Science shows that SPC3649, a breakthrough microRNA-targeted therapy developed by Santaris Pharma A/S using its proprietary Locked Nucleic Acid (LNA) technology, holds promise as a novel treatment for patients infected with the Hepatitis C virus (HCV).

4 Dec 2009

Neurologix completes Phase 2 clinical trial of Parkinson’s study

Neurologix, Inc. (OTCBB:NRGX), a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced the completion of all planned surgeries in an ongoing Phase 2 clinical trial of the company’s gene transfer approach to the treatment of advanced Parkinson’s disease.

4 Dec 2009

Genzyme announces reopening of enrollment in its Pompe disease ATAP program

Genzyme Corporation announced today that it will reopen enrollment in the Alglucosidase Alfa Temporary Access Program (ATAP), a program which provides access to treatment for severely affected adults with Pompe disease prior to commercial approval of Lumizyme™ (alglucosidase alfa). Genzyme and the FDA have also agreed on a path toward approval of Lumizyme.

4 Dec 2009

Protein plays a key role in cancer and DNA repair

A protein that plays a key role in copying DNA also plays a vital role in repairing breaks in it, UC Davis scientists have found. The work is helping researchers understand how cancer cells can resist radiation and chemotherapy, as well as how cells become cancerous in the first place.

4 Dec 2009

GIND scientists identify drug treatments that can normalize neuron development in AD

Scientists at the Gladstone Institute of Neurological Disease (GIND) have discovered that two main causes of AD amyloid-beta (Aβ) peptides and apolipoprotein E4 (apoE4) impair the growth of new neurons born in adult brains. What is more, they have identified drug treatments that can normalize the development of these cells even in the presence of Aβ or apoE4. The findings are described in two separate papers published in the current issue of Cell Stem Cell.

4 Dec 2009

Multi-Lumen MammoSite device to treat breast cancer now available at Jupiter Medical Center

Women fighting breast cancer after a lumpectomy have a new weapon in the battle, now available at Jupiter Medical Center's Foshay Cancer Center. Today, the hospital began treating patients with the Multi-Lumen MammoSite(R) device, just approved in September by the FDA.

4 Dec 2009

The Cancer Center at Harrington receives approval to treat its first patients

The Cancer Center at Harrington has received approval to treat its first patients, Harrington Hospital announced today.

4 Dec 2009

ISIS-FXIRx and ISIS-SMNRx included in Isis Pharmaceuticals' development pipeline

Isis Pharmaceuticals, Inc. announced today that it has added two new drugs to its development pipeline, ISIS-FXIRx and ISIS-SMNRx.

4 Dec 2009

Expert advice for organ transplant surgeons on clinical issues posed by swine flu pandemic

Surgeons and other healthcare professionals specialising in solid organ transplants have been issued with expert advice to guide them through the complex clinical issues posed by the global H1N1 (swine flu) pandemic.

4 Dec 2009

ISTODAX included in the updated NCCN Clinical Practice Guidelines in Oncology

Gloucester Pharmaceuticals announced today that ISTODAX® (romidepsin) has been included in the updated National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology™ as a suggested systemic treatment option for patients with mycosis fungoides and Sézary syndrome—two of the most common types of cutaneous T-cell lymphoma (CTCL).

4 Dec 2009

Sulphonylureas, an antidiabetic drug, carries greater risk of heart failure and death compared to metformin

Research: Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: Retrospective cohort study using UK general practice research database

4 Dec 2009

Researchers discover new strategy against invasive parasite

Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered a possible strategy against an invasive parasite that infects more than a quarter of the world's population, including 50 million Americans.

4 Dec 2009

Combination of green tea and DAPH-12 chemicals may help prevent brain disorders

Scientists at Boston Biomedical Research Institute (BBRI) and the University of Pennsylvania have found that combining two chemicals, one of which is the green tea component EGCG, can prevent and destroy a variety of protein structures known as amyloids. Amyloids are the primary culprits in fatal brain disorders such as Alzheimer's, Huntington's, and Parkinson's diseases.

4 Dec 2009

Study shows younger, female and Hispanic stroke survivors are less likely to take antithrombotic medications

People who have had an ischemic stroke are at higher lifetime risk for another stroke, but several types of medication can reduce that risk. One of the simplest regimens involves antithrombotic medications, otherwise known as blood thinners, of which the most common is aspirin.

3 Dec 2009

States weigh health cuts; Mass. considers student health 'revision'

News outlets report on budget squeezes in Oklahoma and Florida and a proposed overhaul of student health insurance in Massachusetts.

3 Dec 2009

Don't stop dieting during the holiday season

As Americans gear up for the holiday season this month, Dr. Sasson Moulavi, a Board Certified Bariatric Physician, cautions that overweight and obese patients not give in to temptation and forget their dieting. Rather, Dr. Sass, founder of the Smart for Life(R) Cookie Diet, recommends alternative behavior for a positive outcome when it is time to ring in the New Year.

3 Dec 2009

Allos Therapeutics to launch the COMPLETE registry for patients with PTCL

Allos Therapeutics, Inc. today announced the launch of an international registry designed to address the urgent need to better understand treatment patterns and outcomes for patients with peripheral T-cell lymphoma (PTCL). The registry, known as COMPLETE (Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment), is a global observational study that will enroll patients with newly-diagnosed PTCL and obtain data regarding longitudinal treatment patterns and outcomes.

3 Dec 2009

Enrollment closed early in Cubist Pharmaceuticals' ecallantide Phase 2 program

Cubist Pharmaceuticals, Inc. today announced the early closing of enrollment in its ecallantide Phase 2 program. Ecallantide, in development as therapy to reduce bleeding in on-pump cardiac surgery, is now known as CB-500,929. After a regularly scheduled review meeting, the Data Safety Monitoring Board (DSMB) contacted the company to recommend a temporary suspension in enrollment in one of the CB-500,929 trials, CONSERV-2.

3 Dec 2009

Therapy News and Research

Risk of having a potentially fatal blood clot after surgery is higher, finds research

FDA approves St. Jude Medical's MultiSteering Technology software for optimizing neurostimulation therapy

Santaris Pharma's LNA technology based microRNA-targeted therapy holds promise for HCV

Neurologix completes Phase 2 clinical trial of Parkinson’s study

Genzyme announces reopening of enrollment in its Pompe disease ATAP program

Protein plays a key role in cancer and DNA repair

GIND scientists identify drug treatments that can normalize neuron development in AD

Multi-Lumen MammoSite device to treat breast cancer now available at Jupiter Medical Center

The Cancer Center at Harrington receives approval to treat its first patients

ISIS-FXIRx and ISIS-SMNRx included in Isis Pharmaceuticals' development pipeline

Expert advice for organ transplant surgeons on clinical issues posed by swine flu pandemic

ISTODAX included in the updated NCCN Clinical Practice Guidelines in Oncology

Sulphonylureas, an antidiabetic drug, carries greater risk of heart failure and death compared to metformin

Researchers discover new strategy against invasive parasite

Combination of green tea and DAPH-12 chemicals may help prevent brain disorders

Study shows younger, female and Hispanic stroke survivors are less likely to take antithrombotic medications

States weigh health cuts; Mass. considers student health 'revision'

Don't stop dieting during the holiday season

Allos Therapeutics to launch the COMPLETE registry for patients with PTCL

Enrollment closed early in Cubist Pharmaceuticals' ecallantide Phase 2 program

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News